Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

96 results
Display

Docetaxel-loaded PLGA nanoparticles to increase pharmacological sensitivity in MDA-MB-231 and MCF-7 breast cancer cells

Tran P, Nguyen TN, Lee Y, Tran PN, Park JS

This study aimed to develop docetaxel (DTX) loaded poly(lactic-coglycolic acid) (PLGA) nanoparticles (DTX-NPs) and to evaluate the different pharmacological sensitivity of NPs to MCF-7 and MDA-MB-231 breast cancer cells. NPs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report

Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, Sathekge M

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 ( 177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells

Lee SH, Lee YJ

BACKGROUND/OBJECTIVES: The study was conducted to investigate the efficacy of the combination treatment of phytochemical resveratrol and the anticancer drug docetaxel (DTX) on prostate carcinoma LNCaP cells, including factors related...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Current Status of Metastatic Castration-Naïve Prostate Cancer Management

Choi SM, Choi JH, Hwa JS

During last many decades, androgen deprivation therapy (ADT) was the main treatment of choice for metastatic castration-naïve prostate cancer (mCNPC). However, there are now more possible treatment options for mCNPC....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy

Min K, Chung JW, Ha YS, Lee JN, Kim BS, Kim HT, Kim TH, Yoo ES, Kwon TG, Chung SK, Tanaka M, Egawa S, Kimura T, Choi SH

PURPOSE: The purpose of this study was to determine the comparative effectiveness of androgen deprivation therapy (ADT) combined with docetaxel (DTX)-based chemotherapy in Korean and Japanese castration-resistant prostate cancer (CRPC)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Docetaxel rechallenge in metastatic castrationresistant prostate cancer: A retrospective, singlecenter study

Byeon S, Kim H, Kim J, Kwon M, Hur JY, Jeon HG, Jeon SS, Lee HM, Park SH

Purpose: To assess the efficacy and safety of docetaxel rechallenge in the salvage setting in metastatic castration-resistant prostate cancer (mCRPC) patients. Materials and Methods: Clinicopathologic data from patients treated with docetaxel...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer

Won HS, Kim YS, Kim JS, Chang ED, Na SJ, Whang IY, Lee DS

Background/Aims: We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Kim MJ, Kim SM, Jung HA, Hong JY, Chang WJ, Choi MK, Kim HS, Sun JM, Park K, Ahn MJ

BACKGROUND/AIMS: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Choi JH, Choi J, Chung SM, Oh JY, Lee YS, Min KH, Hur GY, Shim JJ, Kang KH, Lee HK, Lee SY

BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study

Kwon WA, Joung JY, Lee JE, Choi SY, Kim SH, Seo HK, Lee KH, Kim CS

PURPOSE: We aimed to evaluate the efficacy and safety of the use of docetaxel plus androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) in Korean patients. MATERIALS AND METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prediction of Acquired Taxane Resistance Using a Personalized Pathway-Based Machine Learning Method

Kim YR, Kim D, Kim SY

PURPOSE: This study was conducted to develop and validate an individualized prediction model for automated detection of acquired taxane resistance (ATR). MATERIALS AND METHODS: Penalized regression, combinedwith an individualized pathway score...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial

Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY

PURPOSE: We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients. MATERIALS AND...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways

Park CH, Han SE, Nam-Goong , Kim YI, Kim ES

BACKGROUND: Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies. Docetaxel, a microtubule stabilizer, is a common chemotherapeutic agent used to treat various metastatic cancers. However, prolonged...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line

Hwang E, Hwang SH, Kim J, Park JH, Oh S, Kim YA, Hwang KT

PURPOSE: This study aimed to validate the synergistic effect of ABT-737 on docetaxel using MDA-MB-231, a triple negative breast cancer (TNBC) cell line overexpressing B-cell lymphoma-2 (Bcl-2). METHODS: Western blot analysis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study

Choi Y, Yun MS, Lim SH, Lee J, Ahn JH, Kim YJ, Park KH, Park YS, Lim HY, An H, Suh DC, Kim YH

PURPOSE: This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer

Lee DH, Kim JH, Seo WI, Nam JK, Kim TN, Oh CK, Kim SD, Park SW, Chung JS, Park SH, Lee W, Sung GT, Chung MK, Chung JI

PURPOSE: This study compared the oncologic results of docetaxel chemotherapy (DOC) in castration-resistant prostate cancer (CRPC) according to continuous addition of androgen deprivation therapy (ADT) during chemotherapy. MATERIALS AND METHODS: We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine

Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, Park SR

PURPOSE: This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer

Jeon YW, Kim TH, Youn HJ, Han S, Jung Y, Gwak G, Park YS, Kim JS, Suh YJ

PURPOSE: The current multicenter phase II study was conducted to evaluate the efficacy and safety of the combination of docetaxel and gemcitabine as neoadjuvant chemotherapy (NAC) for locally advanced breast...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer

Jang HS, Koo KC, Cho KS, Chung BH

PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms

Kang J, Park JH, Lee HJ, Jo U, Park JK, Seo JH, Kim YH, Kim I, Park KH

PURPOSE: Caveolin-1 (CAV-1) expression is more associated with basal-like cancers than estrogen receptor- or ErbB-2-expressing breast cancers. However, the biological relevance of different levels of CAV-1 expression according to subtype...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr